Page 177 - Read Online

Page 22 of 25 Battaglin et al. J Cancer Metastasis Treat 2018;4:12 I http://dx.doi.org/10.20517/2394-4722.2018.04

118 Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R,
Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio
C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting
fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer
2017;117:1269-77.
119 Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen
JH, Schellens JH. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol
2016;34:227-34.
120 Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab
M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and
fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018;103:210-6.
121 Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of
irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
122 Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad
L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal
cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
123 Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Irinotecan pathway genotype analysis
to predict pharmacokinetics. Clin Cancer Res 2003;9:3246-53.
124 Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low
doses also increase risk. Clin Cancer Res 2010;16:3832-42.
125 Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-
analysis. Eur J Cancer 2010;46:1856-65.
126 Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius M. Prediction of
irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011;11:61-71.
127 Del Re M, Cremolini C, Loupakis F, Marmorino F, Citi V, Palombi M, Bergamo F, Schirripa M, Rossini D, Cortesi E, Tomasello G,
Spadi R, Buonadonna A, Amoroso D, Vitello S, Di Donato S, Granetto C, D’Amico M, Danesi R, Falcone A. DPYD c.1905+1G>A and
c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: pharmacogenetic translational analysis from the Phase III TRIBE
study in metastatic colorectal cancer. J Clin Oncol 2015;33:abstr 3532.
128 Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal
cancer: a meta-analysis in Caucasians. Pharmacogenomics J 2014;14:120-9.
129 Campbell JM, Stephenson MD, Bateman E, Peters MD, Keefe DM, Bowen JM. Irinotecan-induced toxicity pharmacogenetics: an
umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J 2017;17:21-8.
130 Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML,
Salgia R, Ratain MJ. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype
of patients with cancer. J Clin Oncol 2014;32:2328-34.
131 Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo
N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S,
Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. A molecularly annotated platform of patient-derived xenografts
(“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508-23.
132 Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel
V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G,
Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Assessment of a HER2 scoring system for colorectal cancer:
results from a validation study. Mod Pathol 2015;28:1481-91.
133 Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani
T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A,
Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab
and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-
of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738-46.
134 Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR,
Shanmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor
receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 2016;34:abstr 3517.
135 Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Picciani B,
Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F.
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res
2017;23:2414-22.
136 US National Library of Medicine. S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients
With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery. Identifier: NCT
NCT03365882. Available from: https://clinicaltrials.gov/ct2/show/NCT03365882 [Last accessed on 17 Jan 2018]
137 Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush
M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M,